Guardant Health (GH) Valuation Check As New Manulife Partnership Expands Shield Testing In Asia

Simply Wall St.03-23

AdvertisementShield launch in Asia puts Guardant Health in focus Guardant Health (GH) is in the spotlight after announcing a partnership with Manulife to offer its Shield multi cancer detection blood ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621276867?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566","is_english":true,"pubTime":"2026-03-23 13:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621276867","market":"hk","top_or_hot":-1,"title":"Guardant Health (GH) Valuation Check As New Manulife Partnership Expands Shield Testing In Asia","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementShield launch in Asia puts Guardant Health in focus Guardant Health (GH) is in the spotlight after announcing a partnership with Manulife to offer its Shield multi cancer detection blood ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/guardant-health-gh-valuation-check-as-new-manulife-partnersh\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Guardant Health (GH) Valuation Check As New Manulife Partnership Expands Shield Testing In Asia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGuardant Health (GH) Valuation Check As New Manulife Partnership Expands Shield Testing In Asia\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-23 13:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/guardant-health-gh-valuation-check-as-new-manulife-partnersh><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementShield launch in Asia puts Guardant Health in focus Guardant Health (GH) is in the spotlight after announcing a partnership with Manulife to offer its Shield multi cancer detection blood ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/guardant-health-gh-valuation-check-as-new-manulife-partnersh\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/guardant-health-gh-valuation-check-as-new-manulife-partnersh","article_id":"2621276867","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/guardant-health-gh-valuation-check-as-new-manulife-partnersh","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2621276867","pubTimestamp":1774242294,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Shield launch in Asia puts Guardant Health in focus\nGuardant Health (GH) is in the spotlight after announcing a partnership with Manulife to offer its Shield multi cancer detection blood test to eligible customers in Hong Kong, Singapore and the Philippines starting in April 2026.\nSee our latest analysis for Guardant Health.\nDespite the Shield news, Guardant Health’s 1-day share price return of a 4.38% decline and 30-day share price return of a 17.38% decline sit alongside a 1-year total...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4196":"保健护理服务","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","BK4585":"ETF&股票定投概念","BK4535":"淡马锡持仓","BK4162":"人寿与健康保险","MFC":"宏利金融","GH":"Guardant Health Inc.","BK4551":"寇图资本持仓"},"translate_title":"宏利新合作伙伴扩大亚洲屏蔽测试，Guardant Health(GH)估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GH":1.5,"MFC":1.5},"content_text":"AdvertisementShield launch in Asia puts Guardant Health in focus Guardant Health (GH) is in the spotlight after announcing a partnership with Manulife to offer its Shield multi cancer detection blood test to eligible customers in Hong Kong, Singapore and the Philippines starting in April 2026. See our latest analysis for Guardant Health. Despite the Shield news, Guardant Health’s 1-day share price return of a 4.38% decline and 30-day share price return of a 17.38% decline sit alongside a 1-year total shareholder return of 84.77% and 3-year total shareholder return of about 2.5x. This combination suggests long-term momentum with recent volatility as investors reassess growth prospects and risk. If Guardant’s Asia push has you thinking more broadly about healthcare technology, this could be a good moment to scan 36 healthcare AI stocks. With Guardant Health posting a 1 year total return of 84.77% yet still trading at what some models suggest is about a 51% intrinsic discount, you have to ask: is there still upside here, or is the market already pricing in future growth? Most Popular Narrative: 36% Undervalued Guardant Health’s most followed narrative pegs fair value at about $132.57 per share versus a last close of $85.18. This frames the stock as meaningfully undervalued using a 6.98% discount rate.  Accelerating adoption of non-invasive blood-based cancer diagnostics is driving substantial growth across Guardant Health's key product lines (Guardant360 Liquid, Reveal, and Shield), expanding the company's total addressable market and supporting high double-digit revenue growth, with continued strong volume momentum and share gains documented for both new and established oncology applications.  Read the complete narrative. Curious what kind of revenue path and margin shift needs to play out for that fair value to hold up? The core narrative leans on aggressive topline expansion, a sharp turn in profitability, and a rich earnings multiple that would usually be reserved for mature compounders. The details behind those assumptions are where the real story sits. Result: Fair Value of $132.57 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, investors still need to watch for high ongoing cash burn and potential dilution, as well as any setback in payer coverage that could cap Shield’s screening ramp. Find out about the key risks to this Guardant Health narrative. Another Take: Multiples Flash A Different Signal Here is the tension. Our fair value work suggests Guardant Health trades at roughly a 51% discount, yet the market is already assigning a rich P/S of 11.4x versus 1.2x for the US Healthcare industry and peers, and a fair ratio of 5.7x. That gap points to meaningful valuation risk if sentiment cools. How much optimism are you really comfortable baking in? See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:GH P/S Ratio as at Mar 2026Next Steps With all that in mind, does the balance of optimism and concern here match your own view, or feel stretched? Take a moment to weigh the company’s potential rewards against the issues on investors’ radar, then review 3 key rewards and 3 important warning signs Looking for more investment ideas? If Guardant Health has sharpened your thinking, do not stop here, broaden your watchlist now so you do not miss other opportunities taking shape.  Target powerful upside potential by scanning companies that screens highlight as screener containing 26 high quality undiscovered gems before they move onto everyone else's radar. Prioritise resilience first by reviewing 70 resilient stocks with low risk scores that score well on downside protection and steadier business profiles. Focus on quality at a reasonable price by checking 54 high quality undervalued stocks that combine solid fundamentals with more modest expectations baked into the share price.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621276867","isCrawlerRequest":true}